FDC Ltd. — Investor Presentation 2021

Nov 26, 2021

Date: November 26, 2021

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 531599

Symbol: FDC

Subject: Intimation of Schedule of Analysts/Investors Virtual Conference Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform that the Company has scheduled a Conference meet with the Analysts/Investors through Audio/Video Conferencing on Thursday, December 02, 2021 at 03:00 p.m. (IST). At the said meeting, the FDC team shall discuss on the Half Yearly Business performance of the Company for the Financial Year 2021-2022.

The Investor Presentation is enclosed herewith and the same shall be made available on the Website of the Company i.e. www.fdcindia.com.

All the participants are requested to pre-register themselves by accessing the below link for Audio/Video Conference Meeting:

Participant Access Link
Click on	https://www.cmeeting.com/web3/meetingRegistration/idbEml
the URL	t8lzWkzNHXYB5Ew/3EWQ2PWL8RDN3E

CORPORATE OFFICE	: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 · Fax: +91-22-2677 3462
	E-mail: fdc@fdcindia.com . Website: www.fdcindia.com
REGISTERED OFFICE	: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax: 0240-255 4299
	E-mail: waluj@fdcindia.com . CIN: L24239MH1940PLC003176

The above scheduled meeting shall be subject to changes in case of exigencies, if any.

Kindly take the above information on record.

For FDC Limited

VARSHARANI RAJARAM KATRE Digitally signed by VARSHARANI RAJARAM KATRE Date: 2021.11.26 18:37:22 +05'30'

Varsharani Katre Company Secretary & Compliance Officer

CORPORATE OFFICE	: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 · Fax: +91-22-2677 3462
	E-mail: fdc@fdcindia.com . Website: www.fdcindia.com
REGISTERED OFFICE	: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA Tel.: 0240-255 4407 / 255 4299 / 255 4967 · Fax: 0240-255 4299
	E-mail: waluj@fdcindia.com . CIN: L24239MH1940PLC003176

FDC LIMITED

Investor Presentation

www.fdcindia.com

This report may contain certain statements that might be considered forward looking. These statements are subject to certain risk and uncertainties, since they are based on certain assumptions and expectations of future events. Actual results may differ materially from those expressed in the statement. The Company cannot guarantee that these assumptions and expectations are accurate and will be realised. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statement.

Platform to deliver sustainable value

Strong Domestic Business

• A. Multiple levers, high growth brands to anchor growth
• B. Zifi Category Creator in CEFIXIME
• C. Electral Category creator & sustained leader in Oral Rehydration Salts
• D. Ophthalmology: legacy strength - 3rd highest in volumes
• E. Strong portfolio of functional foods & energy drinks

Best-in-class manufacturing facilities & regulatory track record

• A. Portfolio of high quality manufacturing facilities
• B. Revenues from multiple geographies, exporting to more than 50 countries.

Sales & Marketing

4,000 Medical representatives across 9 divisions marketing 130+ products

Multiple Top Brands to anchor growth

$1(a)$

Brand	Molecule	Rank	Rs. Crs	MS %
Zifi	Cefixime	Ø	284	24.8
Electral	Oral Rehydration	Ø	283	70.1
Enerzal	Energy Drink	Ø	113	42.2
Zifi CV	Cefixime + Clavulanic acid	Ø	54	40.1
Zocon Tab	Fluconazole	Ø	53	26.7
Amodep AT	Atenolol + Amlodipine	Ø	47	7.7
Zathrin	Azithromycin	Ø	63	4.4
Zifi O	Cefixime + Ofloxacin	Ø	48	11.7
Simyl MCT	Infant Formulas	Ø	23	78.5
Vitcofol	Folic acid + Cyanocobalamin + Nicotinamide	7	78	2.6

Zifi - Category Leader in CEFIXIME

Zifi - Consistent Category Leader

$1_(b)$

In an otherwise fragmented market

6

$1(c)$ Électral - Category Creator & Consistent Leader in Oral Rehydration Salts (WHO Formula)

Electral -Brand synomous with product category

In an otherwise fragmented market

Player Rank

Multiple SKUs to Driving Consistent Growth

Enerzal- Category Leader in Energy Drinks

Enerzal - Consistent Category Leader

$1(d)$

In an otherwise fragmented market

(Market Shares of Other Players)

Market Share in 2019

Player Rank

8

$1(e)$ Zifi CV - Category Leader in Cefixime and Clavulanate Potassium Combination

EDO

Zifi CV- Consistent Category Leader

(Market Share)

In an otherwise fragmented market

(Market Shares of Other Players)

Player Rank

$\rightarrow$ R, Cefixime and Clavulanate Potassium Tablets TiFiCV 200 ज़िफी सी वी २०० 1 x 10 Tablets

Rank by Value

Rank	Company
$\mathbf{1}$	ALLERGAN INDIA LTD
$\overline{2}$	AJANTA PHARMA LTD
3	SUN + RANBAXY
$\overline{4}$	CIPLA LTD
5	NOVARTIS + ALCON
6	ENTOD
$\overline{7}$	MICRO
8	INTAS
9	SUNWAYS
10	FDC Limited

Rank by Volume

Rank	Company
1	CIPLA
2	ALLERGAN INDIA LTD
3	FDC Limited
4	AJANTA Pharma
5	SUN + RANBAXY

High Growth Potential and Functional Food Brands

AWACS Highlights - MAT Sept 2021

As per MAT Sept 2021: $\bullet$

$1(g)$

• $\checkmark$ FDC's Value growth stands at 22.2% against a market growth of 15.2%.
• $\checkmark$ FDC's Volume growth stands at 16.6% against a market growth of $7.1\%$ .
• FDC is ranked the $5^th$ fastest growing company, among the top 25 $\bullet$ corporates, in terms of Value.
• In terms of Volume growth, FDC is ranked the 4^th fastest growing company, $\bullet$ among the top 25 corporates.

Vitamins & Minerals Simyl MCT (ATCC 53103) Cansules Inc Gluconate Oral Drops Zioral_DROC

Covid-19 Special Launches

Other Launches

Manufacturing Facilities & Regulatory Highlights -1

Location

Products

• Sterile ophthalmic preparations
• Oral Liquids
• Oral Rehydration Salts
• External Powders

Regulatory Approvals

• Ophthalmic facility is MHRA GMP approved, Undergone 7 MHRA inspections between 2003 and Sep 2021. Recent virtual inspection was completed between Sep 6-9, 2021 and the Company also received GMP Certificate in November 2021.
• Cleared 6 USFDA inspections since 2005, received Establishment Inspection Report $(EIR)$
• MHRA GMP approved for capsule manufacturing; last MHRA inspection in Sep 2019
• cGMP compliant as per PIC/S Malaysia, last inspection in September 2017
• GMP compliant by MCA-Zimbabwe, last inspection in Sep 2019

• Oral Solid Dosages (Tablet/ Capsules)
• Oral Rehydration Salts

Manufacturing Facilities & Regulatory Highlights -2

Location

$2(a)$

		Œ
	шπ	Ц
FDC
	Goa 3

Products

Oral Solid Dosages (Tablet)

Regulatory Approvals

• MHRA GMP approved; last MHRA inspection in Sep 2019
• cGMP Compliant by PIC's Malaysia. Last $\bullet$ inspection in May 2017

Active Pharmaceutical Ingredients (APIs)

• USFDA approved WHO
• CEP

Manufacturing Facilities & Regulatory Highlights -3

Location

$2(a)$

Sinnar

Products

Oral Rehydration Salt

Food Plant

• Ready to drink Energy drink
• Nutraceuticals
• Protein supplements, Spray dried infant milk supplément

Regulatory Approvals

• WHO, Unicef, Tanzania, Ethiopia, Malawi
• FSSAI, BIS.

• Certified ISO 22000:2005-Food Safety Management System.

• Cephalosporin Oral Solids

• Oral Powders
• Oral Liquids

WHO approved, USFDA compliant

TOP 10 Countries for Export Sale of APIs & Formulations

$2(b)$

$3(a)$ Quarterly Performance

FDO Half Yearly Performance

$3(a)$

in crs. (except RPS)	H1FY22	H1FY20	YoY %
Revenue from operations	841.25	681.63	23%
Other income	54.01	46.74	16%
Total Income	895.26	728.37	23%
Operating Expenses	655.06	470.49	39%
EBITDA	240.20	257.87	-7%
Finance Cost	1.52	1.57	-3%
Depreciation	18.93	19.01	0%
Profit before Tax	219.75	237.29	-7%
Taxes	46.09	55.54	$-17%$
Profit after Tax	173.66	181.75	-4%
EPS (not annualized)	10.29	10.63	-3%

Financial Summary - 5 Year Scenario

$3(b)$

Figures in INR Crores	FY17	FY18	FY19	FY20	FY21
Total Sales	1,046	1,070	1,076	1,323	1,316
Domestic Sales	883	926	902	1,064	993
International Sales	163	144	173	259	323
Sales Growth	5%	2%	0.55%	23%	$-0.53%$
Operating Expenditure	804	851	856	1,048	1,001
EBITDA	292	270	275	366	421
EBITDA Margins	28%	25%	26%	28%	32%
Net Profits	187	168	171	247	294

$3(c)$ Best in Class Operating Financials

Core RoE %

For updates and company information, please visit our website i.e. www.fdcindia.com

For specific queries, kindly email on investors@fdcindia.com

Thank You!